News and Updates by the Food and Drugs Administration (FDA)
Individualized health coaching options are now available for purchase on questhealth.com. Offered through Pack Health, a subsidiary of Quest Diagnostics known for its evidence-based patient interaction services, the platform pairs users with certified health coaches. These professionals offer focused support, […]
***Solventum (NYSE: SOLV), formerly the Health Care division of 3M, has initiated a series of workforce reductions.*** The Star Tribune of Minnesota first reported the development through a video message by CEO Bryan Hanson directed to the Twin Cities headquarters’
Staff Reductions Announced by Solventum Read More »
Today, Withings revealed it has acquired approximately $22.5 million in backing as part of a fresh initiative supported by the French government. Through the France 2030 program, Withings is set to embark on “Project Deep” ( DE vice as a
Withings Secures $22.5M for AI and Medical Device Advancements Read More »
Minneapolis-based ShiraTronics has officially commenced its pivotal FDA investigational device exemption (IDE) trial, aiming to assess its neuromodulation therapy for chronic migraines. The RELIEV-CM2 study marks the beginning of in-depth evaluation regarding the long-term safety and performance of this treatment.
ShiraTronics Kicks Off FDA IDE Trial for Implantable Neuromodulation Therapy Read More »
Edwards Lifesciences (NYSE:EW) shared its ambitious growth trajectory as it transitions into a dedicated structural heart enterprise by 2025. This pivot follows the $4.2 billion divestment of its Critical Care division to BD, inciting a 3% global workforce reduction and
GE HealthCare, renowned for its innovations in medical technology, pharmaceutical diagnostics, and digital solutions, has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for approval of CleaRecon DL. This cutting-edge deep learning technology aims to uplift
RESTEM, a biotechnological firm at the clinical-stage, dedicated to crafting innovative cell therapies that are readily available and aim to regulate the immune response, has disclosed that the United States Food and Drug Administration (FDA) has bestowed Orphan Drug Designation
Dentalkart, the pioneering and largest online hub for dental products in India, has garnered Rs. 85 crore in a recent financing round. This investment, headed by international investors Malabar Investment and Whiteoak, underscores the company’s dedication to transforming the dental
Relay Therapeutics Inc, a precision medicine company specializing in drug discovery through advanced computational and experimental methods, and Elevar Therapeutics Inc, a division under HLB Co Ltd and a comprehensive biopharmaceutical entity committed to enhancing treatment success for patients without
Relay Therapeutics and Elevar Forge Worldwide License for Lirafugratinib Read More »
Everest Medicines, a biopharmaceutical company committed to pioneering the discovery, development, production, and commercialization of novel therapies, has shared promising outcomes from their ongoing phase 1b/2a trial evaluating EVER001 for primary membranous nephropathy (pMN). A cutting-edge covalent reversible Bruton’s tyrosine